TABLE V.
Randomized controlled trials for primary prophylaxis in medical outpatients with cancer
| Trial | Medical setting | Patients(n) | Regimen | Duration of treatment | Outcome | Incidences | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Control | vte | Major bleeding | |||||||||
| Study(%) | Control (%) | p Value | Study (%) | Control (%) | p Value | |||||||
| Levine et al., 1994 38 | Breast cancer stage iv | 311 | Warfarin 1 mg daily for 6 weeks, then adjusted for inr 1.3–1.9 | Placebo | 1 Week after completion of chemotherapy | Symptomatic vte | 0.7 | 4.4 | 0.031 | 5.30 | 3.10 | 0.4 |
| Haas et al., 2005 39 | Advanced breast cancer | 353 | Certoparin 3000 IU daily | Placebo | 6 Months | Ultrasonographic dvt | 4.0 | 3.9 | >0.05 | 1.7 | 0 | >0.05 |
| Advanced non-small-cell lung cancer | 547 | Certoparin 3000 IU daily | Placebo | 6 Months | Ultrasonographic dvt | 4.5 | 8.3 | 0.07 | 3.7 | 2.2 | >0.05 | |
| Perry et al., 2007 40 | Glioma grade iii or iv | 186 | Dalteparin 5000 IU daily | Placebo | 6 Months | pe, symptomatic dvt | 11 | 17 | 0.3 | 5.1 | 1.2 | 0.2 |
vte = venous thromboembolism; dvt = deep vein thrombosis; pe = pulmonary embolism; inr = international normalized ratio.